Related Experiment Videos
Ethambutol in tuberculosis.
1McMaster University, Hamilton, Ontario, Canada.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1990
Summary
Ethambutol, used for tuberculosis treatment, can cause serious vision loss even at standard doses. Due to its unpredictable ocular toxicity and minimal contribution to modern regimens, less toxic alternatives are recommended.
Area of Science:
- Pharmacology
- Ophthalmology
- Infectious Disease
Background:
- Ethambutol was widely adopted for tuberculosis treatment due to better patient tolerance and ease of administration compared to PAS.
- Early concerns about ethambutol's ocular toxicity were primarily associated with higher dosages.
Purpose of the Study:
- To review the ocular toxicity associated with ethambutol, even at conventional doses.
- To evaluate the role of ethambutol in modern tuberculosis therapy.
Main Methods:
- Review of existing literature and case reports on ethambutol-induced optic neuritis.
- Analysis of ethambutol's contribution to current short-course tuberculosis treatment regimens.
Main Results:
- Despite early assumptions, significant visual impairment, including permanent blindness and slow recovery, has been reported with conventional ethambutol dosages.
- The exact mechanism of ethambutol-induced optic neuritis remains unclear, and individual patient susceptibility is unpredictable.
- Ethambutol's role in contemporary short-course tuberculosis regimens is minimal.
Conclusions:
- Ethambutol poses a risk of serious, unpredictable ocular toxicity, even at recommended doses.
- Given its marginal benefit in modern treatment protocols, ethambutol should be substituted with safer alternatives for tuberculosis management.